Sugi Predict

Sugi Predict / Compounds / SCHEMBL19251836

SCHEMBL19251836

SCHEMBL19251836

Cc1ccc2[nH]ccc2c1[N+](=O)[O-]

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 4/20 0.50
▸ ALDH1A1 P00352 7/20 0.47
▸ TDP1 Q9NUW8 2/20 0.47
▸ MAPT P10636 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ CYP3A4 P08684 1/20 0.38
▸ KMT2A Q03164 3/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ PARP1 P09874 1/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ GRIN2D O15399 2/20 0.35
▸ GRIN3B O60391 2/20 0.35
▸ GRIN1 Q05586 2/20 0.35
▸ GRIN2A Q12879 2/20 0.35
▸ GRIN2B Q13224 2/20 0.35
▸ GRIN2C Q14957 2/20 0.35
▸ GRIN3A Q8TCU5 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.33
▸ NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2263267 0.79 ALDH1A1 (0.53) TSHRALDH1A1TDP1LMNACYP3A4
SCHEMBL4384056 0.79 MEN1 (0.47) ALDH1A1TDP1MAPTLMNAKMT2A
SCHEMBL4378605 0.79 ESR1 (0.43) TSHRALDH1A1TDP1MAPTLMNA
SCHEMBL3537387 0.77 ALDH1A1 (0.49) TSHRALDH1A1TDP1MAPTLMNA
SCHEMBL17263930 0.76 TSHR (0.64) TSHRALDH1A1TDP1CYP3A4KMT2A
SCHEMBL3299785 0.75 TDP1 (0.47) TSHRALDH1A1TDP1MAPTLMNA
SCHEMBL15364938 0.74 ALDH1A1 (0.41) TSHRALDH1A1TDP1MAPTLMNA
SCHEMBL4427648 0.73 ALDH1A1 (0.71) TSHRALDH1A1TDP1CYP3A4SMN1; SMN2
SCHEMBL5813540 0.72 NOS1 (0.53) TSHRALDH1A1TDP1MAPTLMNA
SCHEMBL4685683 0.72 ALDH1A1 (0.52) TSHRALDH1A1TDP1CYP3A4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119161324-A Methods and compounds for restoring mutant p53 function 皮姆维制药公司 2024-12-20 — — CN disclosed
US-20220213062-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2022-07-07 — — US disclosed
US-11339141-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2022-05-24 — — US disclosed
US-20210002252-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2021-01-07 — — US disclosed
US-10640485-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2020-05-05 — — US disclosed
US-20190119249-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2019-04-25 — — US disclosed
US-10138219-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS (US) 2018-11-27 — — US disclosed
US-20170240525-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2017-08-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170240525-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, KRAS TSHR 3846/4885ALDH1A1 1538/4885TDP1 92/4885
US-11339141-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, KRAS TSHR 3846/4885ALDH1A1 1538/4885TDP1 92/4885
US-20220213062-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, KRAS TSHR 3846/4885ALDH1A1 1538/4885TDP1 92/4885
US-20190119249-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, KRAS TSHR 3846/4885ALDH1A1 1538/4885TDP1 92/4885
US-10640485-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, KRAS TSHR 3846/4885ALDH1A1 1538/4885TDP1 92/4885
US-20210002252-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, KRAS TSHR 3846/4885ALDH1A1 1538/4885TDP1 92/4885
US-10138219-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, KRAS TSHR 3846/4885ALDH1A1 1538/4885TDP1 92/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.